4-Oxo-piperidine-1-carboxylic acid tert-butylamide | 125541-11-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-Oxo-piperidine-1-carboxylic acid tert-butylamide
• 英文别名: N-tert-butyl-4-oxopiperidine-1-carboxamide
• CAS: 125541-11-9
• 化学式: C₁₀H₁₈N₂O₂
• mdl: MFCD11172258
• 分子量: 198.265
• InChiKey: OSPUGUZOIDZZFN-UHFFFAOYSA-N

物化性质

• 沸点：
  389.2±31.0 °C(Predicted)
• 密度：
  1.079±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  49.4
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  哌啶 、 4-Oxo-piperidine-1-carboxylic acid tert-butylamide 在 titanium(IV) isopropylate 、 sodium tetrahydroborate 作用下， 以50%的产率得到[1,4']Bipiperidinyl-1'-carboxylic acid tert-butylamide
  参考文献：
  名称：

  An improved method for reductive alkylation of amines using titanium(IV) isopropoxide and sodium cyanoborohydride

  摘要：

  DOI：

  10.1021/jo00295a060

文献信息

• [EN] A PROCESS FOR THE PREPARATION OF MORPHOLINO SULFONYL INDOLE DERIVATIVES<br/>[FR] PROCÉDÉ POUR LA PRÉPARATION DE DÉRIVÉS DE MORPHOLINOSULFONYLINDOLE
  申请人：PIRAMAL HEALTHCARE LTD

  公开号：WO2012143874A1

  公开（公告）日：2012-10-26

  The present invention relates to a process for the preparation of the compounds of formula (I) which are morpholino sulphonyl indole derivatives. The compounds of formula (I) are capable of inhibiting, modulating or regulating Insulin-Like-Growth Factor I Receptors or Insulin Receptors. The present invention also relates to the processes for preparation of the pharmaceutically acceptable salts of the compounds of formula (I).

  本发明涉及一种制备式(I)化合物的方法，这些化合物是吗啡啶磺酰基吲哚衍生物。式(I)化合物能够抑制、调节或调控胰岛素样生长因子I受体或胰岛素受体。本发明还涉及制备式(I)化合物的药用可接受盐的方法。
• PROCESS FOR THE PREPARATION OF MORPHOLINO SULFONYL INDOLE DERIVATIVES
  申请人：Mascarenhas Malcolm

  公开号：US20140046059A1

  公开（公告）日：2014-02-13

  The present invention relates to a process for the preparation of the compounds of formula (I) which are morpholino sulphonyl indole derivatives. The compounds of formula (I) are capable of inhibiting, modulating or regulating Insulin-Like-Growth Factor I Receptors or Insulin Receptors. The present invention also relates to the processes for preparation of the pharmaceutically acceptable salts of the compounds of formula (I).

  本发明涉及一种制备公式（I）化合物的方法，该化合物是吗啡啶磺酰基吲哚衍生物。公式（I）化合物能够抑制、调节或调节胰岛素样生长因子I受体或胰岛素受体。本发明还涉及制备公式（I）化合物的药物可接受的盐的方法。
• Insulin-Like Growth Factor-1 Receptor Inhibitors
  申请人：Balachandran Sarala

  公开号：US20140045832A1

  公开（公告）日：2014-02-13

  The present invention relates to compounds that are capable of inhibiting, modulating and/or regulating Insulin-Like-Growth Factor I Receptor and Insulin Receptor. The compounds of the instant invention possess a core structure that comprises a sulfonyl indole moiety. The present invention is also related to the pharmaceutically acceptable salts, hydrates and stereoisomers of these compounds.

  本发明涉及一种能够抑制、调节和/或调节胰岛素样生长因子I受体和胰岛素受体的化合物。本发明的化合物具有包含磺酰基吲哚基团的核心结构。本发明还涉及这些化合物的药学上可接受的盐、水合物和立体异构体。
• MATTSON, RONALD J.;PHAM, KAHNIE M.;LEUCK, DAVID J.;COWEN, KENNETH A., J. ORG. CHEM., 55,(1990) N, C. 2552-2554
  作者：MATTSON, RONALD J.、PHAM, KAHNIE M.、LEUCK, DAVID J.、COWEN, KENNETH A.

  DOI：——

  日期：——
• INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR INHIBITORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP2699567A1

  公开（公告）日：2014-02-26